Loading news...
Exploring the Investment Strategies of John Hussman (Trades, Portfolio) in Q4 2025 John Hussman (Trades, Portfolio) recently submitted the 13F filing for the f
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the sixteen ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating to the company.
Universal Beteiligungs und Servicegesellschaft mbH increased its position in PTC Therapeutics, Inc. (NASDAQ: PTCT) by 6.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 132,101 shares of the biopharmaceutical company's stock after purchasing an additional 7,761 shares
Campbell and CO Investment Adviser LLC cut its holdings in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 77.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,347 shares of the biopharmaceutical company's stock after selling 11,546 shares during the quarter. Campbell
QRG Capital Management Inc. acquired a new position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 34,059 shares of the biopharmaceutical company's stock, valued at approximately $2,090,000. Several other
PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M – – Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance – – 2026 product revenue guidance of $700 – 800M, representing 19 – 36% year-over-year growth – – Strong cash position of approximately $1.94B as of December 31 – WARREN, N.J., Jan. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2026.
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CEO Matthew Klein sold 3,016 shares of PTC Therapeutics stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $77.48, for a total value of $233,679.68. Following the completion of the sale, the chief executive officer owned 396,967 shares of
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CFO Pierre Gravier sold 2,139 shares of the business's stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $76.95, for a total value of $164,596.05. Following the completion of the sale, the chief financial officer owned 90,310
WARREN, N.J., Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee.
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CEO Matthew Klein sold 8,089 shares of PTC Therapeutics stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $76.64, for a total transaction of $619,940.96. Following the transaction, the chief executive officer owned 341,875 shares in the company, valued
Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) insider Eric Pauwels sold 20,508 shares of the business's stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $77.26, for a total transaction of $1,584,448.08. Following the transaction, the insider directly owned 70,373 shares of the company's
– Indication includes all ages and the full spectrum of disease severity – – First Japan product approval for PTC – WARREN, N.J. , Dec. 22, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that Sephience™ (sepiapterin) has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of children and adults living with phenylketonuria (PKU).
Assenagon Asset Management S.A. lessened its position in PTC Therapeutics, Inc. (NASDAQ: PTCT) by 83.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 107,648 shares of the biopharmaceutical company's stock after selling 523,974 shares during the period. Assenagon Asset Management S.A. owned approximately
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) insider Eric Pauwels sold 40,290 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $75.43, for a total transaction of $3,039,074.70. Following the completion of the transaction, the insider owned 70,373 shares in
WARREN, N.J. , Dec. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 3,825 shares of its common stock and 4,385 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to five new employees.
WARREN, N.J. , Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B.
PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
PTC's turnaround quarter is raising eyebrows-here's why one major investor just doubled down.